|
1 David GA, Manuel SG, Luz TA, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias [J]. Blood, 2010, 116 (23): 4783-4785.
|
|
2 Bay A, Oner AF, Uner A, et al. Use of rituximab in chronic childhood immune thrombocytopenic purpura [J]. Pediatr Int, 2006,48(5): 514-516.
|
|
3 Parodi E, Nobili B, Perrotta S, et al. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: Efficacy and safety of treatment[J]. Int J Hematol, 2006, 84(1): 48-53.
|
|
4 Yu JY. Standard of diagnosis and curative effect in haematological practice. //Zhang ZN, Shen T, ed. 3 rd ed[M]. Beijing: Science Publishing House, 2007, 172-176.
|
|
5 Kui LY, Cun SL, Xu J, et al. Analysis of 123 children of idiopathic thrombocytopenic purpura combined with Helicobacter pylori infection [J/CD]. Chin J Obstet Gynecol Pediat (Electron Ed), 2011, 7(2): 114-116.[奎莉越，寸树兰，胥冀，等.儿童特发性血小板减少性紫癜合并幽门螺杆菌感染123例分析[J/CD].中华妇幼临床医学杂志：电子版，2011，7(2)：114-116.]
|
|
6 Wei HW, Wang HM, Han MM, et al. Study on T helper cell polarized populations in children with chronic idiopathic thrombocytopenic purpura [J/CD]. Chin J Obstet Gynecol Pediat (Electron Ed), 2011, 7 (2): 114-116.[魏洪伟，王红美，韩萌萌，等.T辅助细胞极化群体在儿童慢性特发性血小板减少性紫癜发病机制中的作用研究[J/CD].中华妇幼临床医学杂志：电子版，2008,4(1)：27-29.]
|
|
7 Provan D, Butler T, Evangelista ML, et al. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults [ J]. Haematologica, 2007, 92 ( 12): 1695-1698.
|
|
8 Laws HJ, Janssen G, Borkhardt A. Reassessment of treatment modalities for paediatric patients with chronic immune thrombocytopenia[J]. Hamostaseologie, 2009, 29(2): 171-176.
|
|
9 Neunert CE, Bright BC, Buchanan GR. Severe chronic refractory immune thrombocytopenic purpura during childhood: A survey of physician management [J]. Pediatr Blood Cancer, 2008, 51(4):513-516.
|
|
10 Penalver FJ, Jimenez YV, Almagro M, et al. Rituximab in the management of chronic immune thrombocytopenic purpura: An effective and safe therapeutic alternative in refractory patients[J]. Ann Hematol, 2006,85(6) :400-406.
|
|
11 Bennett CM, Rogers ZR, Kinnamon DD, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura[J]. Blood, 2006, 107(7):2639-2642.
|
|
12 Tarantino MD, Bolton-Maggs PH. Update on the management o immune thrombocytopenic purpura in children[J]. Curr Opi Hematol, 2007, 14(5):526-534.
|